HK Stock Market Move | IMPACT THERAP-B(07630) extends gains by over 41%; senaparib internationalization milestone achieved; company's inclusion in Stock Connect expected to continue attracting southbound capital.

IMPACT THERAP-B(07630) extended its gains by over 41%. As of press time, it rose 35.23% to HK$17.62, with a turnover of HK$296 million. On the news front, on September 18, a major positive development materialized for the company: IMPACT Therapeutics and global specialty pharmaceutical company Pharmanovia jointly announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of the marketing authorization (MA) for Sepalna (senaparib), intended for the maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Following the CHMP's recommendation for approval, senaparib will be submitted to the European Commission for a final decision. Once approved by the European Commission, senaparib will be authorized for marketing in all EU member states and European Economic Area countries. In addition, IMPACT Therapeutics was recently included in the Stock Connect eligible list, allowing southbound capital to trade directly, with market attention continuing to rise. Market analysts believe that the recovery in sentiment in the innovative drug sector, combined with the internationalization milestone of senaparib's EMA approval, along with multiple positive factors including Stock Connect inclusion and domestic product ramp-up, has driven active capital deployment.